SKYRIZI (Abbvie Pty Ltd)
Product name
SKYRIZI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
181 (255 working days)
Active ingredients
Risankizumab
Registration type
EOI
Indication
SKYRIZI is now also indicated for the treatment of moderate to severe Crohn’s disease in adult patients, who have an inadequate response, a lost response, an intolerance or a contra-indication to either conventional or biologic therapy.